Clinical trial · Observational
Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
NCT06777290CI-TRIAL-00084707completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to compare the diagnostic performance of whole-body MRI scan, positron emission tomography + CT, and circulating tumor DNA in patients with hematologic malignancy called diffuse large cell B lymphoma (DLBCL) in staging and restaging, and prognosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Diffuse Large B-Cell | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- DLBCL patients
- description
- Adult patients newly diagnosed with diffuse large cell B lymphoma
Primary outcomes (1)
- measure
- Diagnostic accuracy of whole-body MRI in staging of DLBCL
- timeFrame
- at baseline
- description
- Comparison of diagnostic accuracy of whole-body MRI in staging of DLBCL in newly diagnosed adult patients before treatment compared to PET/CT as the gold standard
Secondary outcomes (2)
- measure
- Diagnostic value of MRI sequences
- timeFrame
- At baseline
- description
- Rating of the diagnostic utility of MRI sequences used in whole body MRI in staging of DLBCL in newly diagnosed adult patients before treatment
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * age ≥18 years * performance status according to the Eastern Cooperative Oncology Group between 0 and 3 * satisfactory clinical condition to participate in this study * adequate hematologic and renal functions * no contraindications to MRI * recent or planned PET/CT at the institution * informed consent to participate. Exclusion Criteria: * history of indolent lymphoma * anti-lymphoma treatment initiated before PET/CT or wbMRI * central nervous system lymphoma
References
Publications (1)
- BACKGROUNDLambert L, Burgetova A, Trneny M, Bircakova B, Molinsky J, Benesova K, Zogala D, Michalek P. The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis. Quant Imaging Med Surg. 2022 Feb;12(2):1558-1570. doi: 10.21037/qims-21-649. PMID 35111648